Cargando…
Efficacy of auranofin as an inhibitor of desmoid progression
Anticancer drugs and molecular targeted therapies are used for refractory desmoid-type fibromatosis (DF), but occasionally cause severe side effects. The purpose of this study was to identify an effective drug with fewer side effects against DF by drug repositioning, and evaluate its efficacy. FDA-a...
Autores principales: | Ito, Kan, Nishida, Yoshihiro, Hamada, Shunsuke, Shimizu, Koki, Sakai, Tomohisa, Ohkawara, Bisei, Alman, Benjamin A., Enomoto, Atsushi, Ikuta, Kunihiro, Koike, Hiroshi, Zhang, Jiarui, Ohno, Kinji, Imagama, Shiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279441/ https://www.ncbi.nlm.nih.gov/pubmed/35831372 http://dx.doi.org/10.1038/s41598-022-15756-9 |
Ejemplares similares
-
Less-invasive fascia-preserving surgery for abdominal wall desmoid
por: Nishida, Yoshihiro, et al.
Publicado: (2021) -
Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis
por: Sakai, Tomohisa, et al.
Publicado: (2022) -
Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis
por: Sakai, Tomohisa, et al.
Publicado: (2017) -
Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial
por: Nishida, Yoshihiro, et al.
Publicado: (2020) -
Development of Therapeutic Agent for Osteoarthritis via Inhibition of KIAA1199 Activity: Effect of Ipriflavone In Vivo
por: Zhang, Jiarui, et al.
Publicado: (2023)